
Pipeline
Learn more about our R&D pipeline and ongoing trials below
Development Programs – Solid Tumor
Drug
Indication
Phase 1
Phase 2
Phase 3
BGB-24714 (SMAC Mimetic) +/- Chemotherapy
BGB-3245
(BRAF inhibitor)BGB-26808 (HPK1 inhibitor) +/- Tislelizumab (anti-PD-1)
BGB-30813
(DGKζ inhibitor) +/- TislelizumabBGB-A3055 (anti-CCR8) +/- Tislelizumab
BGB-B167 (CEA-4-1BB bispecific antibody) +/- Tislelizumab
BGB-B167 +/- Tislelizumab
BGB-A445 (anti-OX40) +/- Tislelizumab
Tislelizumab + BGB-A445
BGB-A445 +/- Tislelizumab +/- Sitravatinib (mulitkinase inhibitor) +/- BGB-15025 (HPK1 inhibitor) +/- Chemotherapy
LBL-007 (anti-LAG-3) +/- Tislelizumab + Bevacizumab + Capecitabine*
LBL-007 + Tislelizumab + Chemotherapy*
Lifirafenib (RAF inhibitor) + Mirdametinib
(MEK inhibitor)†Ociperlimab (anti-TIGIT) + Tislelizumab
Ociperlimab + Tislelizumab + BAT1706
(anti-VEGF)Ociperlimab + Tislelizumab + Chemotherapy
Ociperlimab + Tislelizumab + Concurrent Chemoradiotherapy
Pamiparib
(PARP 1/2 inhibitor)Tislelizumab
Tislelizumab +/- Surzebiclimab (anti-TIM-3) +/- LBL-007*
Tislelizumab +/- Surzebiclimab +/- LBL-007*
Tislelizumab +/- Ociperlimab +/- LBL-007*
Tislelizumab +/- BGB-A445 +/- LBL-007 +/- Chemotherapy*
Tislelizumab + BGB-10188
(PI3Kδ inhibitor)Tislelizumab + BGB-15025
(HPK1 inhibitor)Tislelizumab + Chemoradiotherapy
Tislelizumab + Chemotherapy/ Chemoradiotherapy
Tislelizumab + Chemotherapy
Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy**
Tislelizumab + Fruquintinib
(VEGFR inhibitor)‡Tislelizumab + Lenvatinib
(VEGFR kinase inhibitor)Tislelizumab + Sitravatinib
(multikinase inhibitor)Tislelizumab + Surufatinib
(VEGFR, FGFR, CSF-1R inhibitor)‡Zanidatamab
(anti-HER2 bispecific antibody)§Zanidatamab + Chemotherapy +/- Tislelizumab§
*In collaboration with Nanjing Leads Biolabs.
†In collaboration with SpringWorks Therapeutics.
**In collaboration with Leap Therapeutics, Inc.
‡ Clinical collaboration with Hutchison Medipharma International.
§ In collaboration with Zymeworks,Inc.
Safety and efficacy have not been established for investigational products and/or uses.
BC, breast cancer; BTC, biliary tract cancer; CRC, colorectal cancer; CSF-1R, colony stimulating factor-1 receptor; DKK1, Dickkopf-1; EC, endometrial cancer; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR, fibroblast growth factor receptor; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor-2; NSCLC, non–small cell lung cancer; SCLC, small cell lung cancer; UBC, urothelial bladder cancer; VEGFR, vascular endothelial growth factor receptors.
Development Programs – Hematology
Drug
Indication
Phase 1
Phase 2
Phase 3
Tislelizumab
(anti-PD-1)BGB-10188
(PI3Kδ inhibitor) +/- ZanubrutinibSonrotoclax (Bcl-2 inhibitor) monotherapy
Sonrotoclax + Azacitidine +/- Posaconazole
Sonrotoclax + Dexamethasone +/- Carfilzomib
Sonrotoclax + Zanubrutinib
BGB-16673
(BTK-targeted CDAC)Ociperlimab (anti-TIGIT) +/- Tislelizumab or Rituximab
Zanubrutinib
Zanubrutinib + Lenalidomide +/- Rituximab
Zanubrutinib + Obinutuzumab
Zanubrutinib + Rituximab
Safety and efficacy have not been established for investigational products and/or uses.
CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; PI3Kδ, phosphoinositide 3-kinase delta; R/R, recurrent/refractory; TIGIT, T-cell immunoreceptor with Ig and ITIM domains.
Interactive Clinical Pipeline
Videos
PARPI Mechanism of Action
Anti-PD-1 Mechanism of Action
BTKI Mechanism of Action
Anti-TIGIT Mechanism of Action